Press Releases

Press Releases

or

November 26, 2019
CAMBRIDGE, Mass. and BEIJING, China , Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today
November 12, 2019
CAMBRIDGE, Mass. and BEIJING, China , Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
October 31, 2019
• Companies to Collaborate on the Commercialization of XGEVA ® (denosumab), KYPROLIS ® (carfilzomib), and BLINCYTO ® (blinatumomab) in China   • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the